Minnesota based Laplace Interventional, a medical device company developing a transcatheter tricuspid valve technology, announced today that it has closed on its Series A financing led by a non-disclosed major strategic investor along with a significant investment from ShangBay Capital, an early stage medical device investor as well as other investors including Mayo Clinic. The $7.9M Series A financing round will fund Laplace Interventional towards achieving its preclinical milestones. The company also announced the addition of two Directors to its Board including William Dai, Founding Managing Partner at ShangBay Capital.